A Agilent Technologies Inc.

Agilent to Showcase Their Commitment to Sustainability at analytica virtual 2020

(NYSE: A) today announced that their 1220, 1260, and 1290 Infinity II LC product families have received the My Green Lab accountability, consistency, and transparency (ACT) certification. Recognition of these products by My Green Lab highlights Agilent's commitment to pursuing sustainability throughout the production and lifecycle of its analytical equipment. Agilent will showcase these accredited products at the 2020 analytica virtual industry trade fair.

No longer a side topic in science and industry, sustainability has become a key strategic element, especially as part of decisions around the purchase of instruments for "labs of the future." With a growing need – and pressure – to factor in environmental responsibility, more and more labs are seeking ways to reduce their environmental impact through the purchase of more sustainable equipment. Additionally, the success of labs seeking to attract the best personnel is seen as strongly linked to their ability to offer an eco-conscious working environment.

A leader in life sciences, diagnostics, and applied chemical markets, Agilent is amongst the first global analytical instrumentation manufacturing companies to be externally audited for the environmental impact of their gas and liquid chromatographs. These newly certified Agilent products give customers a clearer path for reducing the environmental impact of their labs, while simultaneously improving laboratory working conditions and demonstrating their own commitment to sustainability.

“Innovation is at the forefront of Agilent’s core company values,” said Darlene Solomon, senior vice president, and chief technology officer for Agilent Technologies. “We remain focused on innovation through differentiated laboratory solutions and transformation of the customer experience, and sustainability is a priority. Continuous improvement of our products and services, in terms of the benefits they deliver as well as the environmental impact associated with their production and operation is a key driver of our efforts.”

As a nonprofit organization run "for scientists, by scientists," My Green Lab is dedicated to "fundamentally and permanently improving the sustainability of scientific research." They strive to unify scientists, vendors, designers, energy providers, and others toward research that reflects the highest standards of social and environmental responsibility.

Agilent’s Infinity II liquid chromatography (HPLC) instruments underwent the independent audit process and received their labels in June while the gas chromatography instruments are currently undergoing the certification process. Visit our booth at to see the instruments with their labels, and to find out more.

For more information about the ACT label, visit .

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the Agilent . Follow Agilent on , , and .

EN
19/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch